SMS Lifesciences India Ltd. (SMSLIFE) AI Stock Analysis

• Market Cap: ₹3.39B
• Dividend Yield: 0.13%
• Average Volume (3M): 187.00
• Price to Earnings (P/E): 19.6
• Beta (1Y): 0.67
• Revenue Growth: 3.34%
• EPS Growth: -3.38%
• Country: IN
• Employees: 574
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 13.75
• Shares Outstanding: 3,023,287
• 10 Day Avg. Volume: 150
• 30 Day Avg. Volume: 187
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,198.00
• Price Target Upside: 6.96% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: ₹1,208.00 ▲(7.86% Upside)

SMS Lifesciences India Ltd. shows strong financial performance with growing profitability and efficient equity utilization. However, the technical indicators suggest a bearish trend, and the valuation indicates limited income potential from dividends. These factors combine to give the stock a moderate overall score.

SMS Lifesciences India Ltd. Business Overview & Revenue Model

Company Description

SMS Lifesciences India Limited manufactures, buys, imports, and sells active pharmaceutical ingredients (API) and its intermediates, organic and inorganic chemicals, and pharmaceuticals in India. The company offers APIs in various therapeutic areas, such as antiulcer, antifungal, and erectile dysfunction. It also provides consultancy services. The company exports its products. The company was founded in 1990 and is based in Hyderabad, India.

How the Company Makes Money

SMS Lifesciences India Ltd. generates revenue primarily through the production and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. These products are sold to pharmaceutical companies that use them in the formulation of finished drugs. The company's revenue streams are diversified across several therapeutic areas, including but not limited to anti-inflammatory, anti-fungal, and anti-hypertensive medications. SMSLIFE's earnings are significantly bolstered by its ability to maintain strong relationships with key clients and its adherence to stringent quality standards, which enable it to access regulated markets such as the United States and Europe. Additionally, the company's strategic partnerships and collaborations in research and development contribute to its revenue by facilitating innovation and expanding its product portfolio.

SMS Lifesciences India Ltd. Financial Statement Overview

Summary

SMS Lifesciences India Ltd. demonstrates robust financial health with strong EBIT and EBITDA margins, consistent revenue growth, and improving net profit margins. However, volatility in gross profit margin and historical inconsistencies in cash flow suggest areas for improvement.

Income Statement

SMS Lifesciences India Ltd. shows a strong EBIT and EBITDA margin, with consistent revenue growth over the years. The net profit margin has been improving, indicating enhanced profitability. However, the volatility in gross profit margin suggests potential cost management issues.

Balance Sheet

The company maintains a reasonable debt-to-equity ratio, indicating balanced leverage. The return on equity is solid, reflecting efficient use of equity capital. However, the equity ratio shows a moderate reliance on liabilities, which could pose risks in economic downturns.

Cash Flow

There is a noticeable improvement in free cash flow growth, and the operating cash flow to net income ratio is healthy, suggesting efficient cash conversion. However, historical inconsistencies in cash flow indicate potential volatility in operational cash management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.46B	3.45B	3.06B	3.47B	3.16B	2.57B
Gross Profit	876.16M	505.79M	962.44M	875.42M	875.57M	702.13M
EBITDA	534.20M	498.99M	349.41M	489.11M	341.76M	319.58M
Net Income	230.40M	201.09M	90.93M	253.22M	114.63M	135.57M
Balance Sheet
Total Assets	0.00	3.90B	3.91B	3.57B	3.37B	3.02B
Cash, Cash Equivalents and Short-Term Investments	11.92M	15.08M	5.70M	33.56M	9.54M	106.25M
Total Debt	0.00	864.09M	1.01B	795.98M	869.98M	646.86M
Total Liabilities	-2.03B	1.78B	1.97B	1.92B	1.73B	1.73B
Stockholders Equity	2.03B	1.97B	1.77B	1.52B	1.64B	1.29B
Cash Flow
Free Cash Flow	0.00	144.61M	34.38M	-623.94M	―	-3.87M
Operating Cash Flow	0.00	298.10M	243.06M	-112.41M	―	351.70M
Investing Cash Flow	0.00	-150.61M	-184.50M	-71.43M	―	-262.35M
Financing Cash Flow	0.00	-148.15M	-65.64M	108.33M	―	-25.46M

SMS Lifesciences India Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1120.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SMSLIFE, the sentiment is Negative. The current price of 1120 is below the 20-day moving average (MA) of 1172.82, below the 50-day MA of 1152.74, and below the 200-day MA of 1209.44, indicating a bearish trend. The MACD of 6.49 indicates Positive momentum. The RSI at 41.44 is Neutral, neither overbought nor oversold. The STOCH value of 13.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SMSLIFE.

SMS Lifesciences India Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDICO	66 Neutral	₹4.00B	39.66	16.16%	―	4.15%	21.74%
SMSLIFE	61 Neutral	₹3.39B	19.61	―	0.13%	3.34%	-3.38%
LYKALABS	58 Neutral	₹3.39B	45.17	7.74%	―	19.40%	1286.88%
SMSPHARMA	55 Neutral	₹22.40B	29.99	10.81%	0.16%	10.29%	25.18%
NURECA	48 Neutral	₹2.30B	-76,533.33	0.44%	―	35.84%	-100.52%
BROOKS	42 Neutral	₹4.03B	313.47	-10.16%	―	10.30%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

SMS Lifesciences India Ltd. Corporate Events

SMS Lifesciences Announces Dividend Record Date and Launches Shareholder Engagement Campaign

SMS Lifesciences India Ltd. has announced the record date for its 2024-25 dividend as September 24, 2025, with the dividend payment subject to shareholder approval at the upcoming AGM on September 30, 2025. Additionally, the company has launched the ‘Saksham Niveshak’ campaign to engage shareholders in updating KYC details and claiming unclaimed dividends, aligning with regulatory compliance and investor empowerment initiatives.